<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490620</url>
  </required_header>
  <id_info>
    <org_study_id>Col40296</org_study_id>
    <nct_id>NCT00490620</nct_id>
  </id_info>
  <brief_title>Study of Combivir for Patients With Primary Biliary Cirrhosis</brief_title>
  <official_title>Randomized Controlled Pilot Study of Combivir for Patients With Primary Biliary Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Axcan Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof of principal study to determine whether combination anti-viral therapy with
      Combivir impacts on hepatic biochemistry in patients with primary biliary cirrhosis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A novel human retrovirus has been cloned from a cDNA library derived from biliary epithelia
      cells extracted from patients with Primary Biliary Cirrhosis. Although there is no formal
      proof that this virus is etiologically related to the disease, we have found evidence for
      viral infection in the majority of patients with PBC using standard serologic and
      hybridization assays. In order to address the hypotheses that PBC is etiologically related to
      a retrovirus infection and that anti-retroviral therapy may be beneficial for patients with
      PBC, we have conducted 2 pilot studies using lamivudine and Combivir (lamivudine 150mg and
      Zidovudine 300mg). On the whole, little clinical improvement was observed in patients on
      lamivudine therapy alone, whereas those on Combivir had significant reductions of hepatic
      biochemistry studies and histologic improvement. Moreover, 4 of 10 Combivir patients
      completely normalized their liver function tests and the anti-viral therapy was well
      tolerated. We now propose a larger randomized trial to assess the short term (6 months)
      safety and efficacy of Combivir for patients with PBC. Efficacy in this study will be defined
      using both liver biochemistries and virologic endpoints.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with either (i) normalized alkaline phosphatase, (ii) normalized AST and ALT or (iii) normal alkaline phosphatase, AST and ALT will be recorded.</measure>
    <time_frame>During the 6 months of therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>50% improvement towards baseline for alkaline phosphatase, AST and ALT, changes in symptoms using an objective graded clinical parameter scale, serum AMA titers, quantitative immunoglobulins and virologic parameters.</measure>
    <time_frame>During the 6 months of therapy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>blinded placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antiretroviral therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination antiviral therapy</intervention_name>
    <description>Zidovudine 300mg and lamivudine 150mg BID for 6 months</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Combivir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo BID for 6 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 years old of either sex will be recruited for this study.

          -  Persistently elevated alkaline phosphatase or serum aminotransferases of at least 1.5
             times normal after a minimum of 6 months UDCA therapy.

          -  Positive serum AMA (titer &gt; 1:20).

          -  Liver biopsy histology compatible with PBC obtained at any time prior to study.

          -  Maintained on UDCA at a dose of 13-15 mg/kg for 6 or more months.

          -  Patients must read and sign informed consent form.

        Exclusion Criteria:

          -  Patients treated with immunosuppressive or anti-inflammatory agents such as
             colchicine, methotrexate, D-penicillamine, cyclosporine, tacrolimus, mycophenolate
             mofetil, corticosteroid therapy will be excluded but may enter the study after a 3
             month period off immunosuppressive and anti-inflammatory therapy.

          -  Advanced liver disease: Childs Pugh class B or C cirrhosis, recurrent variceal
             hemorrhage, spontaneous encephalopathy, diuretic resistant ascites, need for liver
             transplantation within the year.

          -  Patients with a secondary hepatic diagnosis such as viral hepatitis, drug induced
             liver injury, extrahepatic biliary obstruction, primary sclerosing cholangitis,
             metabolic liver diseases or alcoholic liver disease.

          -  Regular use of more than 30 g of alcohol per day in the last year.

          -  Patients with a predicted survival of less than 3 years from malignant or other
             potentially life threatening disease.

          -  Creatinine clearance less than &lt; 70 mL/min using the Cockcroft Gault equation:

          -  Clinically apparent pancreatitis.

          -  Serum amylase &gt; 3 x upper limit of normal (patients with sicca syndrome and salivary
             gland disease may have elevated amylase levels)

          -  Pregnancy or breast-feeding a child.

          -  Sexually active patients of child bearing age and not using effective contraception.

          -  Allergic reaction to Combivir like drugs

          -  Clinical evidence of myositis

          -  Weight of &lt; 50 Kg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew L Mason, MBBS MRCPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bruce Bacon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith Lindor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James Neuberger, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Catherine Vincent, MD FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis University</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5N 1Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3C 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>England</state>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mason AL, Farr GH, Xu L, Hubscher SG, Neuberger JM. Pilot studies of single and combination antiretroviral therapy in patients with primary biliary cirrhosis. Am J Gastroenterol. 2004 Dec;99(12):2348-55.</citation>
    <PMID>15571581</PMID>
  </reference>
  <reference>
    <citation>Mason A, Nair S. Primary biliary cirrhosis: new thoughts on pathophysiology and treatment. Curr Gastroenterol Rep. 2002 Feb;4(1):45-51. Review.</citation>
    <PMID>11825541</PMID>
  </reference>
  <reference>
    <citation>Xu L, Shen Z, Guo L, Fodera B, Keogh A, Joplin R, O'Donnell B, Aitken J, Carman W, Neuberger J, Mason A. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8454-9. Epub 2003 Jun 27.</citation>
    <PMID>12832623</PMID>
  </reference>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2007</study_first_posted>
  <last_update_submitted>October 31, 2007</last_update_submitted>
  <last_update_submitted_qc>October 31, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2007</last_update_posted>
  <keyword>primary biliary cirrhosis C06.552.630.400</keyword>
  <keyword>retroviral infection C02.782.815</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

